Floating in situ gelling system for stomach site-specific delivery of clarithromycin to eradicate H. pylori

Journal of Controlled Release

Volumn 125, Issue 1, 2008, Pages 33-41

  Rajinikanth, P S ^a   Mishra, B ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Clarithromycin; Controlled delivery; Floating drug delivery; Gastric residence time; Oral in situ gelling system

Indexed keywords

CALCIUM COMPOUNDS; DEIONIZED WATER; DISEASES; PH;

CLARITHROMYCIN; FLOATING DRUG DELIVERY; GASTRIC RESIDENCE TIME; MICROBIAL CULTURE; ORAL IN SITU GELLING SYSTEM;

CONTROLLED DRUG DELIVERY;

CLARITHROMYCIN;

ANIMAL EXPERIMENT; ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; HELICOBACTER PYLORI; IN VITRO STUDY; MALE; NONHUMAN; PH; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; CLARITHROMYCIN; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG STABILITY; GELS; GERBILLINAE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HYDROGEN-ION CONCENTRATION; MALE; POLYSACCHARIDES, BACTERIAL; SOLUBILITY; STOMACH; SUCRALFATE; VISCOSITY;

EID: 36649003296     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2007.07.011     Document Type: Article

References (36)

1. Marshall B.J., and Warren J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1 (1984) 1311-1315
2. Peterson W.L. Helicobacter pylori and peptic ulcer disease. N. Engl. J. Med. 324 (1991) 1043-1048
3. Umamaheshwari R.B., Jain N.K., and Jain S. A new approach in gastroretentive drug delivery system using cholestyramine. Drug Deliv. 10 (2003) 151-160
4. Labenz J. Current role of acid suppressants in Helicobacter pylori eradication therapy. Best Pract. Res. Clin. Gastroenterol. 15 (2001) 413-431
5. Lin C.K., Hsu P.I., and Lai K.H. One-week quadruple therapy is an effective salvage regimen for Helicobactere pylori infection in patients after failure of standard triple therapy. J. Clin. Gastroenterol. 34 5 (2002) 547-551
6. Kawabami E., Ogata S.K., and Portorreal A.C. Triple therapy with clarithromycin, amoxicillin and omeprazole for Helicobacter pylori eradication in children and adolescents. Arq. Gastroenterol 38 3 (2001) 203-206
7. Cuna M., Alonso M.J., and Torres D. Preparation and in vivo evaluation of mucoadhesive microparticles containing amoxicillin-resin complexes for drug delivery to the gastric mucosa. Eur. J. Pharm. Biopharm. 51 (2001) 199-205
8. Hirayama F., Takagi S., Kusuhara H., et al. Induction of gastric ulcer and intestinal metaplasia in Mongolian gerbils infected with Helicobacter pylori. J. Gastroenterol. 31 (1996) 755-757
9. Rajinikanth P.S., Balasubramanium J., and Mishra B. Development and evaluation a novel floating in situ gelling system of amoxicillin for eradicating of Helicobacter pylori. Int. J. Pharm. 335 (2007) 114-122
10. Hollander D., and Tytgat G.N.J. Sucralfate: from Basic Science to the Bedside (1995), Plenum Press, New York, N.Y.
11. Adachi K.S., Ishihara T., Hashimoto K., Hirakawa M., Niigaki T., Takashima T., Kaji A., Kawamura H., Sato T., Okuyama M., and Kinoshita Y. Efficacy of sucralfate for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen. Aliment. Pharmacol. Ther. 14 (2000) 919-922
12. Tarnawski A.D., Hollander W.J., Krause R.D., Zipser J., and Gergely H. Does sucralfate affect the normal gastric mucosa? Histologic, ultrastructural, and functional assessment in the rat. Gastroenterology 90 (1986) 893-905
13. Myung K.C., Hongkee S., and Hoo-Kyun C. Preparation of mucoadhesive microspheres containing antimicrobial agents for eradication of H. pylori. Int. J. Pharm. 297 (2005) 172-179
14. Jansson P.E., Lindberg B., and Sandford P.A. Structural studies of gellan gum an extracellular polysaccharide elaborated by Pseudomonas elodea. Carbohydr. Res. 124 (1983) 135-139
15. Miyazaki S., Kubo W., and Attwood D. Oral sustained delivery of theophylline using in-situ gelation of sodium alginate. J. Control. Release 67 (2000) 275-280
16. Tanigake A., Miyanaga Y., Nnakamura T., TsujiI E., Matsuyama K., Kuntitomo M., and Uchida T. The bitterness intensity of clarithromycin evaluated by a taste sensor. Chem. Pharm. Bull. 51 11 (2003) 1241-1245
17. Nagahara N., Akiyama Y., Nakao M., Tada M., Kitano M., and Ogawa Y. Mucoadhesive microspheres containing amoxicillin for clearance of Helicobacter pylori. Antimicrob. Agents Chemother. 42 10 (1998) 2492-2494
18. Kusuhara H., Hirayama F., Matsuyuki M., Hisadomw M., and Ikeda Y. Evaluation of combined antibiotic-omeprazole therapies in Helicobacter pylori-infected Mongolian gerbils. J. Gastroenterol. 33 (1998) 14-17
19. Deshpande A.A., Shah N.H., Rhodes C.T., and Malick W. Development of a novel controlled-release system for gastric retention. Pharm. Res. 14 (1997) 815-819
20. Choi B.Y., Park H.J., Hwang S.J., and Park J.B. Biological interactions between divalent cation and polysaccharides. Int. J. Pharm. 239 (2002) 81-91
21. Kedzierewicz F., Lombry C., Rios R., Hoffman M., and Maincent P. Effect of the formulation on the in vitro release of propranolol from gellan beads. Int. J. Pharm. 178 (1999) 129-136
22. Moorehouse R., Cotegrove G.T., Sandford P.A., Baird J.K., and Kang K.S. A new gel-forming polysaccharide. ACS Symp. Ser. 150 (1981) 111-124
23. Deasy P.B., and Quigley K.J. Functionality testing of gellan gum a polymeric recipients material for ophthalmic dosage forms. Int. J. Pharm. 73 (1991) 117-123
24. Miyazaki S., Aoyama H., Kawasaki N., Kudo W., and Attwood D. In situ gelling gellan formulation as vehicle for oral delivery. J. Control. Release 67 (1999) 275-280
25. Tang J., Tung M.A., and Zeng Y. Gelling properties of gellan solution containing monovalent and divalent cations. J. Food Sci. 62 4 (1996) 688-692
26. Grasdalen H., and Smidsroed O. Gellation of gellan gum. Carbohydr. Polym. 7 (1987) 371-393
27. Singh B.M., and Kim K.H. Effect of monovalent and divalent cations on the rheological properties of gellan gels. J. Control. Release 63 (2000) 235-259
28. Higuchi W.I. Mechanism of sustained action medication. J. Pharm. Sci. 51 (1962) 802-804
29. Korsmeyer R.W., Gurney R., Doelker E., Buri P., and Peppas N.A. Mechanisms of solute release from porous hydrophilic polymers. J. Pharm. Sci. 15 (1983) 25-35
30. Erah P.O., Goddard A.F., Barrett D.A., Shaw P.N., and Spiller R.C. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J. Antimicrob. Chemother. 39 1 (1997) 5-12
31. Nakagawa Y., Itai S., Yoshida T., and Nagai T. Physicochemical properties and stability in the acidic solution of a new macrolide antibiotic, clarithromycin, in comparison with erythromycin. Chem. Pharm. Bull. 40 (1992) 725-728
32. Hoeschele J.D., Roy A.K., Pecoraro V.L., and Carver P.L. In vitro analysis of the interaction between sucralfate and ketoconazole. Antimicrob. Agents Chemother. 38 2 (1994) 319-325
33. Watanabe K., Murakami K., Sato R., Kashimura K., Miura M., Ootsu S., Miyajima H., et al. Effect of sucralfate on antibiotic therapy for Helicobacter pylori infection in mice. Antimicrob. Agents Chemother. 48 12 (2004) 4582-4588
34. Lam S.K., Hu W.H., and Ching C.K. Sucralfate in Helicobacter pylori eradication strategies. Scand. J. Gastroenterol., Suppl. 210 (1995) 89-91
35. Adachi K., Ishihara S., Hashimoto T., Hirakawa K., Niigaki M., Takashima T., Kaji T., Kawamura A., Sato H., Okuyama T., Watanabe M., and Kinoshita Y. Efficacy of sucralfate for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen. Aliment. Pharmacol. Ther. 14 (2000) 919-922
36. Slomiany A., Piotrowski J., and Slomiany B.L. Sucralfate counteracts the inhibition of gastric mucosal mucin receptor by Helicobacter pylori lipopolysaccharide. Scand. J. Gastroenterol., Suppl. 210 (1995) 77-81